Share

Copy the link

In recent years, the number of new drugs entering the market has been declining and this is in-part the result of the current state of preclinical research. Outcomes of preclinical studies today are modest; it is estimated that only 1 in 10 drugs will continue along the drug discovery pipeline into phase II clinical trials.

Preclinical tests aim to answer three questions about the drug: what does the drug do in the body; what does the body do to the drug; and if it is potent, is it also safe? With these, researchers work to provide an accurate model of the biological activity of the drug in humans.

This spotlight will aim to review recent advancements and current obstacles in existing and novel techniques applied to preclinical studies. We will delve into the development of novel methods for assessing the preclinical viability of lead compounds; we will consider what is essential for preclinical testing of efficacy, tolerability and safety before first-in-human clinical trials and discuss what changes may take place with these methods in the coming years//how these methods are likely to evolve and change in the future.

Thank you to all those who took part in our survey and shares their thoughts on preclinical testing. If you haven't yet, please take a moment to complete the survey; it should take a maximum of 10 minutes to complete.

We will be sharing the results of the survey later in the spotlight. See how you compare to others around the world!